Genomic Testing Cooperative and their Cooperative Member Laboratories Expand Hematology Panels to Cover VEXAS Disease and a New Prognostic Biomarker in Myeloproliferative Neoplasms
March 2, 2022
IRVINE, California, March 2, 2022, Genomic Testing Cooperative, LCA (GTC) announced today that their hematology molecular profiling is expanded to cover analysis of the UBA1 and NFE2 genes. Both genes were recently reported to be clinically important for the diagnosis and treatment of patients with hematologic neoplasms. Recently described VEXAS (vacuoles, E1